Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight
' Diabetic Macular Edema Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.
The Diabetic Macular Edema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Macular Edema Pipeline Report:
Companies across the globe are diligently working toward developing novel Diabetic Macular Edema treatment therapies with a considerable amount of success over the years.
Diabetic Macular Edema companies working in the treatment market are Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma, Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others, are developing therapies for the Diabetic Macular Edema treatment
Emerging Diabetic Macular Edema therapies in the different phases of clinical trials are- EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others are expected to have a significant impact on the Diabetic Macular Edema market in the coming years.
In March 2025, Unity Biotechnology reported topline results from its Phase 2b ASPIRE clinical trial evaluating intravitreal UBX1325 in patients with diabetic macular edema (DME) who continued to experience poor vision despite prior anti-VEGF therapy. The trial data includes outcomes for all participants through 24 weeks and most through 36 weeks. ASPIRE (NCT06011798) is a multi-center, randomized, double-masked, active-controlled Phase 2b study. A total of 52 patients were enrolled and randomly assigned in a 1:1 ratio to receive either 10 μg of UBX1325 or 2 mg of aflibercept every 8 weeks for six months following randomization.
In March 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness-related conditions, announced that the Data and Safety Monitoring Board (DSMB) has reviewed safety data from the first cohort in the dose-escalation phase of its Phase 1 OCU200 clinical trial. Based on this evaluation, the DSMB has given the green light to begin dosing the second cohort. OCU200 is an innovative fusion protein combining tumstatin and transferrin, being developed as a potential therapy for diabetic macular edema (DME).
In February 2025, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), focused on developing innovative therapies for serious retinal diseases, has shared promising six-month data from its ongoing Phase 2 VERONA trial of DURAVYU™ (vorolanib intravitreal insert). This investigational, sustained-release treatment utilizes the company's proprietary bioerodible Durasert E™ platform to deliver the selective tyrosine kinase inhibitor, vorolanib. The study successfully met its primary endpoint by significantly delaying the need for supplemental injections compared to the aflibercept control group in both DURAVYU dosage arms. Notably, patients experienced sustained visual improvement and anatomical stability, with no serious ocular or systemic adverse events related to DURAVYU. At week 24, the 2.7mg dose group achieved a +7.1 letter improvement in best corrected visual acuity (BCVA) and a 76-micron decrease in central subfield thickness (CST), with 73% of patients avoiding supplemental injections versus 50% in the aflibercept group. These results highlight DURAVYU's strong therapeutic promise for treating severe retinal conditions.
In January 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology firm focused on developing cutting-edge gene and cell therapies, biologics, and vaccines, has announced that the first patient has been successfully dosed in its Phase 1 clinical trial of OCU200, a potential treatment for diabetic macular edema (DME).
Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is a complication of diabetes that affects the eyes. It occurs when the macula, which is the central part of the retina responsible for sharp, central vision, swells due to the accumulation of fluid. DME is a type of diabetic retinopathy, a condition that can affect individuals with diabetes.
Emerging Diabetic Macular Edema Drugs Under Different Phases of Clinical Development Include:
EB-102: Eluminex BioSciences
OCU200: Ocugen
IBI324: Innovent biologics
CU06-1004: Curacle
GSK-2798745: GlaxoSmithKline
EXN407: Exonate Limited
APX3330: Ocuphire Pharma
UBX1325: Unity Biotechnology
AG-73305: Allgenesis Biotherapeutics Inc.
MYL-1701P: Mylan
KSI-301: Kodiak Sciences
BEOVU (RTH258; brolucizumab): Novartis
VABYSMO (faricimab): Roche
KSI-301: Kodiak Sciences
ADVM-022: Adverum Biotechnologies
GB-102: Graybug Vision
THR-149: Oxurion
LKA651: Novartis
YD-312: YD Life Science
Luminate (ALG-1001, Risuteganib): Allegro Opthalmics/Bausch Health
Xipere (CLS-TA): Clearside Biomedical
KVD001: KalVista Pharmaceuticals
Diabetic Macular Edema Pipeline Therapeutics Assessment
Diabetic Macular Edema Assessment by Product Type
Diabetic Macular Edema By Stage and Product Type
Diabetic Macular Edema Assessment by Route of Administration
Diabetic Macular Edema By Stage and Route of Administration
Diabetic Macular Edema Assessment by Molecule Type
Diabetic Macular Edema by Stage and Molecule Type
DelveInsight's Diabetic Macular Edema Report covers around products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Diabetic Macular Edema product details are provided in the report. Download the Diabetic Macular Edema pipeline report to learn more about the emerging Diabetic Macular Edema therapies
Some of the key companies in the Diabetic Macular Edema Therapeutics Market include:
Key companies developing therapies for Diabetic Macular Edema are - Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Allegro Opthalmics, Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others.
Diabetic Macular Edema Pipeline Analysis:
The Diabetic Macular Edema pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema Treatment.
Diabetic Macular Edema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetic Macular Edema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Diabetic Macular Edema Pipeline Market Drivers
Growing Prevalence of diabetes, development of novel therapies, investment in Research and Development activities are some of the important factors that are fueling the Diabetic Macular Edema Market.
Diabetic Macular Edema Pipeline Market Barriers
However, high medical cost, lack of approved therapies and other factors are creating obstacles in the Diabetic Macular Edema Market growth.
Scope of Diabetic Macular Edema Pipeline Drug Insight
Coverage: Global
Key Diabetic Macular Edema Companies: Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma, Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others
Key Diabetic Macular Edema Therapies: EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others
Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies
Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers
Table of Contents
1. Diabetic Macular Edema Report Introduction
2. Diabetic Macular Edema Executive Summary
3. Diabetic Macular Edema Overview
4. Diabetic Macular Edema- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Macular Edema Pipeline Therapeutics
6. Diabetic Macular Edema Late Stage Products (Phase II/III)
7. Diabetic Macular Edema Mid Stage Products (Phase II)
8. Diabetic Macular Edema Early Stage Products (Phase I)
9. Diabetic Macular Edema Preclinical Stage Products
10. Diabetic Macular Edema Therapeutics Assessment
11. Diabetic Macular Edema Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Macular Edema Key Companies
14. Diabetic Macular Edema Key Products
15. Diabetic Macular Edema Unmet Needs
16 . Diabetic Macular Edema Market Drivers and Barriers
17. Diabetic Macular Edema Future Perspectives and Conclusion
18. Diabetic Macular Edema Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 hours ago
- Globe and Mail
Pulmatrix (PULM) Q2 Revenue Falls 100%
Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
12 hours ago
- Globe and Mail
Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Pulmonary Fibrosis Pipeline Insight 2025' report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook Key Takeaways from the Pulmonary Fibrosis Pipeline Report In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo. In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis. DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment. The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs Pulmonary Fibrosis Emerging Drugs Profile BMS-986278: Bristol-Myers Squibb BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis. AK3280: Ark Biosciences Inc. AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. LYT-100: PureTech Health LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. ARO-MMP7: Sarepta Therapeutics ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. TRK-250: Toray Industries, Inc TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. The Pulmonary Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment. Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs Pulmonary Fibrosis Companies Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Pulmonary Fibrosis Products have been categorized under various Molecule types such as Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers Scope of the Pulmonary Fibrosis Pipeline Report Coverage- Global Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Pulmonary Fibrosis: Overview Therapeutic Assessment Pulmonary Fibrosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) BMS-986278: Bristol-Myers Squibb Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK3280: Ark Biosciences Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products RSBT 001: RS BioTherapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Fibrosis Key Companies Pulmonary Fibrosis Key Products Pulmonary Fibrosis- Unmet Needs Pulmonary Fibrosis- Market Drivers and Barriers Pulmonary Fibrosis- Future Perspectives and Conclusion Pulmonary Fibrosis Analyst Views Pulmonary Fibrosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
a day ago
- Globe and Mail
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Endometriosis pipeline constitutes 18+ key companies continuously working towards developing 20+ Endometriosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Endometriosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market. The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Endometriosis Pipeline Report: Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years. Endometriosis companies working in the treatment market are Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment Emerging Endometriosis therapies in the different phases of clinical trials are- FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years. In July 2025, A drug candidate once described by Organon as its 'biggest potential opportunity' failed in a Phase 2 clinical trial, leading the company to discontinue its development for Endometriosis. Organon, a women's health-focused company, acquired the candidate OG-6219 through its $75 million acquisition of Forendo Pharma in 2021, shortly after spinning off from Merck & Co. The company launched a Phase 2 trial in 2022, enrolling 354 premenopausal women suffering from moderate to severe Endometriosis-related pain. Participants were randomized to receive one of three doses of OG-6219 or a placebo. Organon had hoped the drug would alleviate pain by inhibiting a hormone involved in uterine tissue growth and inflammation, but the trial failed to meet expectations. In March 2025, The first long-term daily oral treatment for Endometriosis has been recommended for routine use on the NHS in England. In its final draft guidance, the National Institute for Health and Care Excellence (NICE) advised that relugolix-estradiol-norethisterone, also known as relugolix combination therapy (relugolix CT), should be offered to adults of reproductive age whose Endometriosis symptoms persist despite previous medical or surgical treatments. This marks the first time a daily pill of this kind has been approved for long-term Endometriosis management by the NHS, with around 1,000 women expected to benefit each year. In October 2024, Lisata Therapeutics, Inc. entered into a sponsored research collaboration with the University of Cincinnati to explore its innovative cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor). The study will utilize a preclinical animal model to evaluate the potential of this combination therapy for treating Endometriosis. In October 2024, Hope Medicine Inc. reported positive findings from an interim analysis of its global Phase II trial, titled "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period." HMI-115, a monoclonal antibody that inhibits the prolactin receptor, represents a first-in-class therapy for Endometriosis. Notably, the National Medical Products Administration (NMPA) in China has granted HMI-115 Breakthrough Therapy Designation. In May 2024, Neurocrine Biosciences, Inc. has commenced its Phase I first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational drug NBI-1117567 in healthy adults. NBI-1117567 is an experimental oral selective muscarinic agonist, with a preference for M1 over M4 receptors, being developed as a potential treatment for neurological and neuropsychiatric disorders In May 2024, TiumBio Co., Ltd., a company dedicated to developing innovative treatments for rare and incurable diseases, reported positive topline results from its Phase 2a clinical trial evaluating Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe Endometriosis-associated pain. In April 2024, By the end of this year, Gynica, an Israeli company, plans to administer the first dose in a Phase I trial for its cannabinoid-based therapies, IntraVagS301 and IntraVagS302, designed for Endometriosis. This trial aims to assess the safety, toxicity, and pharmacokinetics of these drugs, which utilize microencapsulation technology Endometriosis Overview Endometriosis is a chronic medical condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often on the ovaries, fallopian tubes, and other pelvic organs. This tissue responds to hormonal changes and can cause pain, inflammation, scar tissue, and fertility issues. Common symptoms include severe menstrual cramps and pelvic pain. Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include: Endometriosis Route of Administration Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Endometriosis Molecule Type Endometriosis Products have been categorized under various Molecule types, such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Endometriosis Pipeline Therapeutics Assessment Endometriosis Assessment by Product Type Endometriosis By Stage and Product Type Endometriosis Assessment by Route of Administration Endometriosis By Stage and Route of Administration Endometriosis Assessment by Molecule Type Endometriosis by Stage and Molecule Type DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Some of the key companies in the Endometriosis Therapeutics Market include: Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others. Endometriosis Pipeline Analysis: The Endometriosis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment. Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Endometriosis Pipeline Market Drivers The development of drug delivery systems represents a new approach in pain treatment among Endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market. Endometriosis Pipeline Market Barriers However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth. Scope of Endometriosis Pipeline Drug Insight Coverage: Global Key Endometriosis Companies: Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others Key Endometriosis Therapies: FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers Table of Contents 1. Endometriosis Report Introduction 2. Endometriosis Executive Summary 3. Endometriosis Overview 4. Endometriosis- Analytical Perspective In-depth Commercial Assessment 5. Endometriosis Pipeline Therapeutics 6. Endometriosis Late Stage Products (Phase II/III) 7. Endometriosis Mid Stage Products (Phase II) 8. Endometriosis Early Stage Products (Phase I) 9. Endometriosis Preclinical Stage Products 10. Endometriosis Therapeutics Assessment 11. Endometriosis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Endometriosis Key Companies 14. Endometriosis Key Products 15. Endometriosis Unmet Needs 16 . Endometriosis Market Drivers and Barriers 17. Endometriosis Future Perspectives and Conclusion 18. Endometriosis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
